CVKD

Cadrenal Therapeutics, Inc.
CAPPED RATING

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Cadrenal Therapeutics, Inc. (CVKD) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
1.9 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
C-
Factor Score 2.0 / 5.0
Profitability
D-
Factor Score 0.9 / 5.0
Momentum
D
Factor Score 1.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.4
EV / EBITDA -0.2
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -21.7%
Price Return 12M -88.1%
Catalyst Signal 0.00
Market Cap $4.5M
TTM Revenue N/A
Price / Sales N/A
ROE -275.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C+ (2.5) C- (2.0) D- (0.9) D (1.5) C+ (2.6) C- (1.9)
2026-11-04 C+ (2.5) C- (2.0) D- (1.0) D- (0.9) C+ (2.7) D+ (1.8)
2026-10-28 C+ (2.5) C- (2.0) D- (1.0) F (0.7) C+ (2.7) D+ (1.8)
2026-10-21 C+ (2.5) C- (2.0) D- (0.9) D- (0.7) C+ (2.6) D+ (1.7)
2026-10-14 C+ (2.5) C- (2.0) D- (0.9) F (0.6) C+ (2.6) D+ (1.7)
Page 1 of 4